CeriBell (CBLL) vs Medtronic (MDT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CeriBell (CBLL) has outperformed Medtronic (MDT) over the past year, gaining 89.1% versus a loss of 10.3%. Medtronic is the larger company by market cap ($112.24 billion vs $888.5 million), about 126.3 times the size. Medtronic pays a dividend yielding 3.25%, while CeriBell does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBLL | MDT |
|---|---|---|
| Share price | $23.15 | $87.75 |
| Market cap | $888.45M | $112.24B |
| 1-day change | -1.41% | +2.62% |
| YTD return | +5.56% | -8.65% |
| 1-year return | +89.13% | -10.34% |
| 5-year return | — | -31.31% |
| P/E ratio (TTM) | — | 21.56 |
| Forward P/E | — | 13.68 |
| EPS (TTM) | $-1.76 | $4.07 |
| Dividend yield | 0.00% | 3.25% |
| Annual dividend | $0.00 | $2.85 |
| Revenue (latest FY) | — | $36.36B |
| Revenue growth (YoY) | — | +8.43% |
| Net income (latest FY) | — | $4.80B |
| Gross margin | — | 65.02% |
| Operating margin | — | 17.78% |
| Net margin | — | 13.20% |
| 52-week high | $25.63 | $106.33 |
| 52-week low | $10.85 | $73.31 |
| Distance from 52-week high | -9.67% | -17.47% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +23.41% | +19.02% |
| Average volume | 368.86K | 11.49M |
| Shares outstanding | 38.38M | 1.28B |
| Employees | 327 | 95,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Medtronic is about 126.3 times larger than CeriBell by market value ($112.24B vs $888.45M).
- CBLL has outperformed MDT by 99.5 percentage points over the past year.
- Medtronic offers a meaningfully higher dividend yield (3.25% vs 0.00%).
About CeriBell
CBLL stock →CeriBell, Inc. operates as a medical technology company in the United States.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 327 employees
About Medtronic
MDT stock →Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 95,000 employees
CBLL vs MDT FAQ
Which is bigger, CeriBell or Medtronic?
Medtronic (MDT) is larger, with a market capitalization of $112.24B compared with $888.45M for CeriBell (CBLL).
Which stock has performed better over the past year, CBLL or MDT?
CBLL returned +89.13% over the past 12 months, compared with -10.34% for MDT (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, CeriBell or Medtronic?
Medtronic pays a dividend yielding 3.25%, while CeriBell does not currently pay a regular dividend.
Are CeriBell and Medtronic in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.